Immunic appoints biopharmaceutical executive Jon Congleton to board

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has announced the assignment of seasoned biopharmaceutical enforcement Jon Congleton to its committee of directors, arsenic the institution advances its aggregate sclerosis programme done late-stage development.

Congleton brings astir 4 decades of acquisition successful the biopharmaceutical industry, with a inheritance spanning cause development, commercialization, and enforcement leadership, according to Immunic.

His enactment has covered aggregate therapeutic areas, including cardiovascular, gastrointestinal, and cardinal tense strategy (CNS) conditions.

During his career, Congleton was progressive successful the US motorboat of Copaxone, a attraction for relapsing forms of aggregate sclerosis (MS) developed by Teva Pharmaceuticals Industries. He aboriginal led US operations for the merchandise arsenic it became 1 of the astir wide prescribed MS therapies.

Congleton presently serves arsenic main enforcement serviceman of Mineralys Therapeutics, wherever helium has overseen the company’s modulation from a private-stage steadfast to a publically traded biotechnology company.

His erstwhile enactment roles see serving arsenic CEO of Impel NeuroPharma and Nivalis Therapeutics. Earlier successful his career, helium held elder positions astatine Teva, including enactment of its North American neuroscience concern and planetary CNS franchise.

“Jon's heavy CNS expertise and proven way grounds successful late-stage cause improvement and commercialization volition beryllium invaluable arsenic we beforehand vidofludimus calcium done its pivotal objective milestones and toward imaginable regulatory support and commercialized launch," said Simona Skerjanec, interim chairperson of Immunic’s committee of directors.

"I americium thrilled that Jon is joining america astatine this captious infinitesimal arsenic we germinate our Board to enactment Immunic successful its modulation into a afloat integrated commercial-stage company."

Congleton described vidofludimus calcium arsenic a “potentially transformative opportunity” for MS patients, noting its advantages implicit presently disposable therapies.

“I look guardant to moving with the Board and the enactment squad and contributing my acquisition to enactment Immunic arsenic it advances toward the pivotal proceedings readouts aboriginal this twelvemonth and semipermanent worth creation,” Congleton said.